Brokerages Set Altimmune, Inc. (NASDAQ:ALT) Price Target at $20.83

Altimmune, Inc. (NASDAQ:ALT - Get Free Report) has received an average recommendation of "Moderate Buy" from the nine analysts that are currently covering the firm, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation, six have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $20.83.

Several equities analysts have recently weighed in on the company. UBS Group assumed coverage on Altimmune in a report on Tuesday, November 12th. They set a "buy" rating and a $26.00 price target on the stock. William Blair assumed coverage on Altimmune in a report on Friday. They set a "market perform" rating on the stock. HC Wainwright reissued a "buy" rating and set a $12.00 price target on shares of Altimmune in a report on Wednesday, February 5th. Finally, Stifel Nicolaus initiated coverage on Altimmune in a research note on Wednesday, January 8th. They issued a "buy" rating and a $18.00 price objective for the company.

Altimmune Stock Performance

Shares of NASDAQ ALT traded up $0.23 during midday trading on Wednesday, hitting $6.65. 3,370,041 shares of the stock traded hands, compared to its average volume of 2,242,734. The firm has a 50-day moving average of $6.85 and a two-hundred day moving average of $7.19. The firm has a market capitalization of $472.98 million, a P/E ratio of -4.29 and a beta of 0.19. Altimmune has a one year low of $5.28 and a one year high of $14.05.

Altimmune (NASDAQ:ALT - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.33) earnings per share for the quarter, beating the consensus estimate of ($0.34) by $0.01. The firm had revenue of $0.01 million for the quarter, compared to analysts' expectations of $0.00 million. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. Equities analysts forecast that Altimmune will post -1.35 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Altimmune

Several hedge funds have recently made changes to their positions in the company. Larson Financial Group LLC purchased a new stake in shares of Altimmune during the 3rd quarter worth about $31,000. SBI Securities Co. Ltd. acquired a new stake in Altimmune in the 4th quarter valued at about $45,000. Virtus ETF Advisers LLC acquired a new stake in shares of Altimmune during the 4th quarter worth approximately $60,000. Cullen Frost Bankers Inc. acquired a new stake in shares of Altimmune during the 4th quarter worth approximately $72,000. Finally, 180 Wealth Advisors LLC acquired a new stake in shares of Altimmune during the 4th quarter worth approximately $78,000. 78.05% of the stock is owned by institutional investors and hedge funds.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.